U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sharma M, Clark H, Armour T, et al. Acute Stroke: Evaluation and Treatment. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Jul. (Evidence Reports/Technology Assessments, No. 127.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Acute Stroke: Evaluation and Treatment

Acute Stroke: Evaluation and Treatment.

Show details

References and Included Studies

1.
The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988; 41(2):105–114. [PubMed: 3335877]
2.
van GJ, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. [Review] [288 refs] Brain. 2001;124(Pt 2):249–278. [PubMed: 11157554]
3.
Matchar, D. B. and Samsa, G. P. Secondary and Teritary Prevention of Stroke. Patient Outcomes Research Team(PORT) Final Report Phase 1. Rockville, MD USA: Agency for Healthcare Research and Quality., 2000.
4.
The surveillance of Stroke The WHO STEPwise Approach. 2002.
5.
Alberts MJ, Hademenos G, Latchaw RE. et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA. 2000;283(23):3102–3109. [PubMed: 10865305]
6.
Brice JH, Griswell JK, Delbridge TR. et al. Stroke: from recognition by the public to management by emergency medical services. [Review] [32 refs] Prehosp Emerg Care. 2002;6(1):99–106. [PubMed: 11789659]
7.
American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Available at: http://www.americanheart.org/ Dallas, Texas: American Heart Association. 2003.
8.
Broderick JP. William M. Feinberg Lecture: stroke therapy in the year 2025: burden, breakthroughs, and barriers to progress. Stroke. 2004;35(1):205–211. [PubMed: 14671248]
9.
Heart and Stroke Foundation of Canada. The Changing Face of Heart Disease and Stroke in Canada. 1999. Ottawa, Canada, Heart and Stroke Foundation of Canada.
10.
Bonita R, Stewart A, Beaglehole R. International trends in stroke mortality: 1970-1985. Stroke. 1990;21(7):989–992. [PubMed: 2368114]
11.
McGovern PG, Burke GL, Sprafka JM. et al. Trends in mortality, morbidity, and risk factor levels for stroke from 1960 through 1990. The Minnesota Heart Survey. JAMA. 1992;268(6):753–759. [PubMed: 1640576]
12.
Wolf PA, D'Agostino RB, O'Neal MA. et al. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke. 1992;23(11):1551–1555. [PubMed: 1440701]
13.
Wolfe CD, Burney PG. Is stroke mortality on the decline in England? Am J Epidemiol. 1992;136(5):558–565. [PubMed: 1442719]
14.
Whisnant JP. The decline of stroke. Stroke. 1984;15(1):160–168. [PubMed: 6364462]
15.
Ostfeld AM. A review of stroke epidemiology. Epidemiol Rev. 1980;2:136–152. [PubMed: 7000533]
16.
Broderick JP, Phillips SJ, Whisnant JP. et al. Incidence rates of stroke in the eighties: the end of the decline in stroke? Stroke. 1989;20(5):577–582. [PubMed: 2718196]
17.
Brown RD, Whisnant JP, Sicks JD. et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27(3):373–380. [PubMed: 8610298]
18.
Khaw KT. Epidemiology of stroke. J Neurol Neurosurg Psychiatry. 1996;61(4):333–338. [PMC free article: PMC486569] [PubMed: 8890767]
19.
Kissela B, Schneider A, Kleindorfer D. et al. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke. 2004;35(2):426–431. [PubMed: 14757893]
20.
Schneider AT, Kissela B, Woo D. et al. Ischemic stroke subtypes: a population-based study of incidence rates among blacks and whites. Stroke. 2004;35(7):1552–1556. [PubMed: 15155974]
21.
Kissela B, Broderick J, Woo D. et al. Greater Cincinnati/Northern Kentucky Stroke Study: volume of first-ever ischemic stroke among blacks in a population-based study. Stroke. 2001;32(6):1285–1290. [PubMed: 11387488]
22.
Howard G, Anderson R, Sorlie P. et al. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. Stroke. 1994;25(11):2120–2125. [PubMed: 7974531]
23.
Stewart JA, Dundas R, Howard RS. et al. Ethnic differences in incidence of stroke: prospective study with stroke register. BMJ. 1999;318(7189):967–971. [PMC free article: PMC27822] [PubMed: 10195965]
24.
Gale CR, Martyn CN. The conundrum of time trends in stroke. J R Soc Med. 1997;90(3):138–143. [PMC free article: PMC1296178] [PubMed: 9135611]
25.
Stegmayr B, Asplund K. Exploring the declining case fatality in acute stroke. Population-based observations in the northern Sweden MONICA Project. J Intern Med. 1996;240(3):143–149. [PubMed: 8862123]
26.
Stegmayr B, Asplund K, Wester PO. Trends in incidence, case-fatality rate, and severity of stroke in northern Sweden, 1985-1991. Stroke. 1994;25(9):1738–1745. [PubMed: 8073452]
27.
Kurtzke JF. Epidemiology of Cerebrovascular Disease. 1969.
28.
Garraway WM, Whisnant JP, Furlan AJ. et al. The declining incidence of stroke. N Engl J Med. 1979;300(9):449–452. [PubMed: 759935]
29.
MacMahon S, Peto R, Cutler J. et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–774. [PubMed: 1969518]
30.
Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995; 346(8991–8992):1647–1653. [PubMed: 8551820]
31.
MacMahon S, Cutler JA, Stamler J. Antihypertensive drug treatment. Potential, expected, and observed effects on stroke and on coronary heart disease. [Review] [27 refs] Hypertension. 1989;13(5 Suppl):I45–I50. [PubMed: 2490828]
32.
Chapman N, Huxley R, Anderson C. et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke. 2004;35(1):116–121. [PubMed: 14671247]
33.
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.[see comment][erratum appears in JAMA 2002 Dec 18;288(23):2976]. JAMA 2000; 283(15):1967–1975. [PubMed: 10789664]
34.
Fagard R, Lijnen P, Vanhees L. et al. Hemodynamic response to converting enzyme inhibition at rest and exercise in humans. Journal of Applied Physiology: Respiratory, Environmental & Exercise Physiology. 1982;53(3):576–581. [PubMed: 6290435]
35.
Abbott RD, Donahue RP, MacMahon SW. et al. Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA. 1987;257(7):949–952. [PubMed: 3806877]
36.
Tuomilehto J, Rastenyte D, Jousilahti P. et al. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke. 1996;27(2):210–215. [PubMed: 8571411]
37.
Robbins AS, Manson JE, Lee IM. et al. Cigarette smoking and stroke in a cohort of U.S. male physicians. Ann Intern Med. 1994;120(6):458–462. [PubMed: 8311368]
38.
Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989;298(6676):789–794. [PMC free article: PMC1836102] [PubMed: 2496858]
39.
Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia. 1995;38(9):1061–1068. [PubMed: 8591820]
40.
Perry IJ, Refsum H, Morris RW. et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346(8987):1395–1398. [PubMed: 7475822]
41.
Iso H, Jacobs DR Jr., Wentworth D. et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320(14):904–910. [PubMed: 2619783]
42.
Lawrence I. Continuing education. Diabetic Medicine. 2004;21(Suppl. 1):1–2. [PubMed: 12647832]
43.
Kiely DK, Wolf PA, Cupples LA. et al. Familial aggregation of stroke. The Framingham Study. Stroke. 1993;24(9):1366–1371. [PubMed: 8362432]
44.
Wade DT. Stroke (acute cerebrovascular disease). Health Care Needs Asessment. 1994. Oxford, Radcliffe Medical Press.
45.
Stegmayr B, Asplund K, Kuulasmaa K. et al. Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project. An ecological study of 18 populations. Stroke. 1997;28(7):1367–1374. [PubMed: 9227685]
46.
The Brain Attack Coalition. Available at: www​.stroke-site.org 2004.
47.
Lee SJ, Lee KH, Na DG. et al. Multiphasic helical computed tomography predicts subsequent development of severe brain edema in acute ischemic stroke. Arch Neurol. 2004;61(4):505–509. [PubMed: 15096397]
48.
Ministry of Health and Long-Term Care and the Heart and Stroke Foundation of Ontario. Towards an integrated Stroke Strategy for Ontario: The Report of the Joint Stroke Strategy Working Group. 2000.
49.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.[see comment]. N Engl J Med 1995; 333(24):1581–1587. [PubMed: 7477192]
50.
Barber M, Langhorne P, Stott DJ. Barriers to delivery of thrombolysis for acute stroke. Age Ageing. 2004;33(2):94–95. [PubMed: 14960419]
51.
Barber PA, Zhang J, Demchuk AM. et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56(8):1015–1020. [PubMed: 11320171]
52.
Silver FL, Rubini F, Black D. et al. Advertising strategies to increase public knowledge of the warning signs of stroke.[see comment] Stroke. 2003;34(8):1965–1968. [PubMed: 12855823]
53.
Ingall TJ, O'Fallon WM, Asplund K. et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35(10):2418–2424. [PubMed: 15345796]
54.
Johnston KC, Connors AJ, Wagner DP. et al. Risk adjustment effect on stroke clinical trials. Stroke. 2004;35(2):e43–e45. [PMC free article: PMC2764275] [PubMed: 14715975]
55.
Marler J, Tilley BC, Lu Y. et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55(11):1649–1655. [PubMed: 11113218]
56.
Hakim AM, Hogan MJ, Carpenter S. Time course of cerebral blood flow and histological outcome after focal cerebral ischemia in rats. Stroke. 1992;23(8):1138–1143. [PubMed: 1636189]
57.
Hakim AM. The cerebral ischemic penumbra. Can J Neurol Sci. 1987;14(4):557–559. [PubMed: 2446732]
58.
Marler G, LB Medicine. Stroke--tPA and the clinic. Science. 2003;301(5640):1677. [PubMed: 14500967]
59.
Hill MD. The Canadian Activase in Stroke Effectiveness Study (CASES). 2004. [PubMed: 11513342]
60.
Engelstein E, Margulies J, Jeret JS. Lack of t-PA use for acute ischemic stroke in a community hospital: high incidence of exclusion criteria.[see comment] Am J Emerg Med. 2000;18(3):257–260. [PubMed: 10830678]
61.
Dafer RM, Tietjen GE, Korsnack A. Experience with rtPA at a Small Medical Center. Neurology. 1998;50:A115.
62.
Pepe PE, Zachariah BS, Sayre MR. et al. Ensuring the chain of recovery for stroke in your community. Chain of Recovery Writing Group. [Review] [19 refs] Prehosp Emerg Care. 1998;2(2):89–95. [PubMed: 9709325]
63.
Schneider AT, Pancioli AM, Khoury JC. et al. Trends in community knowledge of the warning signs and risk factors for stroke. JAMA. 2003;289(3):343–346. [PubMed: 12525235]
64.
Williams LS, Bruno A, Rouch D. et al. Stroke patients' knowledge of stroke. Influence on time to presentation. Stroke. 1997;28(5):912–915. [PubMed: 9158624]
65.
Wein TH, Staub L, Felberg R. et al. Activation of emergency medical services for acute stroke in a nonurban population: the T.L.L. Temple Foundation Stroke Project. Stroke. 2000;31(8):1925–1928. [PubMed: 10926958]
66.
Carrozzella J, Jauch EC. Emergency stroke management: a new era. [Review] [27 refs] Nursing Clinics of North America. 2002;37(1):35–57. [PubMed: 11818260]
67.
Clark WM, Wissman S, Albers GW. et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.[see comment] JAMA. 1999;282(21):2019–2026. [PubMed: 10591384]
68.
Goldstein LB, Edwards MG, Wood DP. Delay between stroke onset and emergency department evaluation. Neuroepidemiology. 2001;20(3):196–200. [PubMed: 11490166]
69.
Luepker RV, Raczynski JM, Osganian S. et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA. 2000;284(1):60–67. [PubMed: 10872014]
70.
Castaldo JE, Nelson JJ, Reed JF. et al. The delay in reporting symptoms of carotid artery stenosis in an at-risk population. The Asymptomatic Carotid Atherosclerosis Study experience: a statement of concern regarding watchful waiting. Arch Neurol. 1997;54(10):1267–1271. [PubMed: 9341573]
71.
DeLemos CD, Atkinson RP, Croopnick SL. et al. How effective are “community” stroke screening programs at improving stroke knowledge and prevention practices? Results of a 3-month follow-up study. Stroke. 2003;34(12):e247–e249. [PubMed: 14631093]
72.
Katzan IL, Furlan AJ, Lloyd LE. et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.[see comment] JAMA. 2000;283(9):1151–1158. [PubMed: 10703777]
73.
Katzan IL, Hammer MD, Furlan AJ. et al. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke. 2003;34(3):799–800. [PubMed: 12624312]
74.
Moher D, Pham B, Lawson ML. et al. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess. 2003;7(41):1–90. [PubMed: 14670218]
75.
Moher D, Pham B, Klassen TP. et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol. 2000;53(9):964–972. [PubMed: 11004423]
76.
Egger M, Juni P, Bartlett C. et al. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess. 2003;7(1):1–76. [PubMed: 12583822]
77.
Moher D, Cook DJ, Eastwood S. et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896–1900. [PubMed: 10584742]
78.
Moher D, Pham B, Jones A. et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–613. [PubMed: 9746022]
79.
Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350(9072):185–186. [PubMed: 9250191]
80.
Neely KW, Norton RL. Survey of health maintenance organization instructions to members concerning emergency department and 911 use.[see comment] Annals of Emergency Medicine. 1999;34(1):19–24. [PubMed: 10381990]
81.
Moher D, Cook DJ, Jadad AR et al. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess 1999; 3(12):i–98. [PubMed: 10374081]
82.
Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. [PubMed: 8721797]
83.
Schulz KF, Chalmers I, Hayes RJ. et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412. [PubMed: 7823387]
84.
The Newcastle-Ottawa Scale(NOS)for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews: Beyond the Basics, Oxford 2000. 00 Jan 7; 2000.
85.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. [PubMed: 12111919]
86.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. [PubMed: 3802833]
87.
Morgenstern LB, Frankowski RF, Shedden P. et al. Surgical treatment for intracerebral hemorrhage (STICH): a single-center, randomized clinical trial. Neurology. 1998;51(5):1359–1363. [PubMed: 9818860]
88.
Teernstra OP, Evers SM, Lodder J. et al. Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: a multicenter randomized controlled trial (SICHPA). Stroke. 2003;34(4):968–974. [PubMed: 12649510]
89.
Zuccarello M, Brott T, Derex L. et al. Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study.[see comment] Stroke. 1999;30(9):1833–1839. [PubMed: 10471432]
90.
Kay R, Poon WS, Nicholls MG. Effect of intravenous ketanserin on arterial and intracranial pressures in patients with systemic hypertension following intracerebral haemorrhage. J Hum Hypertens. 1993;7(4):369–371. [PubMed: 8410928]
91.
Nishiyama T, Yokoyama T, Matsukawa T. et al. Continuous nicardipine infusion to control blood pressure after evacuation of acute cerebral hemorrhage. Can J Anaesth. 2000;47(12):1196–1201. [PubMed: 11132741]
92.
Furlan A, Higashida R, Wechsler L. et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.[see comment] JAMA. 1999;282(21):2003–2011. [PubMed: 10591382]
93.
Keris V, Rudnicka S, Vorona V. et al. Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol. 2001;22(2):352–358. [PMC free article: PMC7973942] [PubMed: 11156782]
94.
Lewandowski CA, Frankel M, Tomsick TA. et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30(12):2598–2605. [PubMed: 10582984]
95.
Gray CS, Hildreth AJ, Alberti GK. et al. Poststroke hyperglycemia: natural history and immediate management. Stroke. 2004;35(1):122–126. [PubMed: 14671236]
96.
Scott JF, Robinson GM, French JM. et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke. 1999;30(4):793–799. [PubMed: 10187881]
97.
Eggers J, Koch B, Meyer K. et al. Effect of ultrasound on thrombolysis of middle cerebral artery occlusion. Ann Neurol. 2003;53(6):797–800. [PubMed: 12783427]
98.
Schmidt H, Fazekas F, Kostner GM. et al. Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke. 2001;32(2):405–412. [PubMed: 11157174]
99.
Albers GW, Clark WM, Madden KP. et al. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.[see comment] Stroke. 2002;33(2):493–495. [PubMed: 11823658]
100.
Hermier M, Nighoghossian N, Adeleine P. et al. Early magnetic resonance imaging prediction of arterial recanalization and late infarct volume in acute carotid artery stroke. J Cereb Blood Flow Metab. 2003;23(2):240–248. [PubMed: 12571455]
101.
Suarez JI, Zaidat OO, Sunshine JL. et al. Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes. Neurosurgery. 2002;50(2):251–259. [PubMed: 11844259]
102.
Kilpatrick MM, Yonas H, Goldstein S. et al. CT-based assessment of acute stroke: CT, CT angiography, and xenon-enhanced CT cerebral blood flow.[see comment] Stroke. 2001;32(11):2543–2549. [PubMed: 11692014]
103.
Morgenstern LB, Bartholomew LK, Grotta JC. et al. Sustained benefit of a community and professional intervention to increase acute stroke therapy. Arch Intern Med. 2003;163(18):2198–2202. [PubMed: 14557217]
104.
Hill MD, Barber PA, Demchuk AM. et al. Building a “brain attack” team to administer thrombolytic therapy for acute ischemic stroke. CMAJ. 2000;162(11):1589–1593. [PMC free article: PMC1231342] [PubMed: 10862236]
105.
Lattimore SU, Chalela J, Davis L. et al. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience. Stroke. 2003;34(6):e55–e57. [PubMed: 12750543]
106.
Smith RW, Scott PA, Grant RJ. et al. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis. Acad Emerg Med. 1999;6(6):618–625. [PubMed: 10386679]
107.
Hacke W, Kaste M, Fieschi C. et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.[see comment] Lancet. 1998;352(9136):1245–1251. [PubMed: 9788453]
108.
Hacke W, Kaste M, Fieschi C. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)[see comment] JAMA. 1995;274(13):1017–1025. [PubMed: 7563451]
109.
Kase CS, Furlan AJ, Wechsler LR. et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001;57(9):1603–1610. [PubMed: 11706099]
110.
del Zoppo GJ, Higashida RT, Furlan AJ. et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.[see comment] Stroke. 1998;29(1):4–11. [PubMed: 9445320]
111.
t AV, Molina CA, Grotta JC. et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351(21):2170–2178. [PubMed: 15548777]
112.
Clark WM, Albers GW, Madden KP. et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000;31(4):811–816. [PubMed: 10753980]
113.
Haley EJ, Brott TG, Sheppard GL. et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke. 1993;24(7):1000–1004. [PubMed: 8322373]
114.
Patel SC, Levine SR, Tilley BC. et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.[see comment] JAMA. 2001;286(22):2830–2838. [PubMed: 11735758]
115.
Roberts HC, Dillon WP, Furlan AJ. et al. Computed tomographic findings in patients undergoing intra-arterial thrombolysis for acute ischemic stroke due to middle cerebral artery occlusion: results from the PROACT II trial.[see comment] Stroke. 2002;33(6):1557–1565. [PubMed: 12052991]
116.
Agarwal PK. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis. 2004;17(23):182–190. [PubMed: 14707420]
117.
Akins PT, Delemos C, Wentworth D. et al. Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke? Neurology. 2000;55(12):1801–1805. [PubMed: 11134376]
118.
Jahnke HK, Zadrozny D, Garrity T. et al. Stroke teams and acute stroke pathways: one emergency department's two-year experience. J Emerg Nurs. 2003;29(2):133–139. [PubMed: 12660695]
119.
Auer LM, Deinsberger W, Niederkorn K. et al. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study. J Neurosurg. 1989;70(4):530–535. [PubMed: 2926492]
120.
Batjer HH, Reisch JS, Allen BC. et al. Failure of surgery to improve outcome in hypertensive putaminal hemorrhage. A prospective randomized trial. Arch Neurol. 1990;47(10):1103–1106. [PubMed: 2222242]
121.
Juvela S, Heiskanen O, Poranen A. et al. The treatment of spontaneous intracerebral hemorrhage. A prospective randomized trial of surgical and conservative treatment.[see comment] J Neurosurg. 1989;70(5):755–758. [PubMed: 2651586]
122.
Mendelow AD, Gregson BA, Fernandes HM. et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365(9457):387–397. [PubMed: 15680453]
123.
Tan SH, Ng PY, Yeo TT. et al. Hypertensive basal ganglia hemorrhage: a prospective study comparing surgical and nonsurgical management. Surg Neurol. 2001;56(5):287–292. [PubMed: 11749988]
124.
Hardemark HG, Wesslen N, Persson L. Influence of clinical factors, CT findings and early management on outcome in supratentorial intracerebral hemorrhage. Cerebrovasc Dis. 1999;9(1):10–21. [PubMed: 9873158]
125.
Schaller C, Rohde V, Meyer B. et al. Stereotactic puncture and lysis of spontaneous intracerebral hemorrhage using recombinant tissue-plasminogen activator. Neurosurgery. 1995;36(2):328–333. [PubMed: 7731513]
126.
Da PR, Bazzan A, Pasqualin A. Surgical versus medical treatment of spontaneous posterior fossa haematomas: a cooperative study on 205 cases. Neurol Res. 1984;6(3):145–151. [PubMed: 6151139]
127.
Kaya RA, Turkmenoglu O, Ziyal IM. et al. The effects on prognosis of surgical treatment of hypertensive putaminal hematomas through transsylvian transinsular approach. Surg Neurol. 2003;59(3):176–183. [PubMed: 12681546]
128.
Muiz AJ, Abdullah J, Naing NN. et al. Spontaneous intracerebral hemorrhage in northeast Malaysian patients: a four-year study. Neuroepidemiology. 2003;22(3):184–195. [PubMed: 12711851]
129.
Deinsberger W, Lang C, Hornig C. et al. Stereotactic aspiration and fibrinolysis of spontaneous supratentorial intracerebral hematomas versus conservative treatment: a matched-pair study. Zentralbl Neurochir. 2003;64(4):145–150. [PubMed: 14634878]
130.
Kurtsoy A, Oktem IS, Koc RK. et al. Surgical treatment of thalamic hematomas via the contralateral transcallosal approach. Neurosurg Rev. 2001;24(23):108–113. [PubMed: 11485230]
131.
Mahaffey KW, Granger CB, Sloan MA. et al. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. Am Heart J. 1999;138(3 Pt 1):493–499. [PubMed: 10467200]
132.
McCarron MO, Nicoll JA, Love S. et al. Surgical intervention, biopsy and APOE genotype in cerebral amyloid angiopathy-related haemorrhage. Br J Neurosurg. 1999;13(5):462–467. [PubMed: 10627776]
133.
Sakas DE, Singounas EG, Karvounis PC. Spontaneous intracerebral haematomas: surgical versus conservative treatment based on Glascow Coma Scale score and computer tomography data. J Neurosurg Sci. 1989;33(2):165–172. [PubMed: 2795189]
134.
Cohen ZR, Ram Z, Knoller N. et al. Management and outcome of non-traumatic cerebellar haemorrhage. Cerebrovasc Dis. 2002;14(34):207–213. [PubMed: 12403953]
135.
Iwamoto N, Kusaka M, Tsurutani T. et al. Ultrasound imaging for stereotactic evacuation of hypertension-associated intracerebral hematomas with aqua-stream and aspiration. Stereotact Funct Neurosurg. 1993;60(4):194–204. [PubMed: 8327798]
136.
Roux FE, Boetto S, Tremoulet M. Third ventriculocisternostomy in cerebellar haematomas. Acta Neurochir (Wien). 2002;144(4):337–342. [PubMed: 12021879]
137.
Siddique MS, Fernandes HM, Arene NU. et al. Changes in cerebral blood flow as measured by HMPAO SPECT in patients following spontaneous intracerebral haemorrhage. Acta Neurochir Suppl. 2000;76:517–520. [PubMed: 11450081]
138.
Tyler D, Mandybur G. Interventional MRI-guided stereotactic aspiration of acute/subacute intracerebral hematomas. Stereotact Funct Neurosurg. 1999;72(24):129–135. [PubMed: 10853064]
139.
Ziai WC, Port JD, Cowan JA. et al. Decompressive craniectomy for intractable cerebral edema: experience of a single center. J Neurosurg Anesthesiol. 2003;15(1):25–32. [PubMed: 12499979]
140.
Kim MH, Kim EY, Song JH. et al. Surgical options of hypertensive intracerebral hematoma: stereotactic endoscopic removal versus stereotactic catheter drainage. J Korean Med Sci. 1998;13(5):533–540. [PMC free article: PMC3054516] [PubMed: 9811185]
141.
Juvela S. Risk factors for impaired outcome after spontaneous intracerebral hemorrhage. Arch Neurol. 1995;52(12):1193–1200. [PubMed: 7492294]
142.
Brott T, Broderick J, Kothari R. et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1–5. [PubMed: 8996478]
143.
Mendelow AD. Investigators and the Steering Committee. The International Surgical Trial in Intracerebral Haemorrhage (ISTICH). Acta Neurochir Suppl. 2003;86:441–443. [PubMed: 14753482]
144.
Kuroda K, Kuwata N, Sato N. et al. Changes in cerebral blood flow accompanied with reduction of blood pressure treatment in patients with hypertensive intracerebral hemorrhages. Neurol Res. 1997;19(2):169–173. [PubMed: 9175147]
145.
Ito H, Arakawa M, Shibasaki T. et al. Acute antihypertensive effect of nifedipine by sublingual route in cases with clinically severe systolic hypertension. A study up to 4 h after administration. Arzneimittelforschung. 1984;34(5):630–636. [PubMed: 6380506]
146.
Patel RV, Kertland HR, Jahns BE. et al. Labetalol: response and safety in critically ill hemorrhagic stroke patients. Ann Pharmacother. 1993;27(2):180–181. [PubMed: 8439694]
147.
Powers WJ, Zazulia AR, Videen TO. et al. Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage.[see comment] Neurology. 2001;57(1):18–24. [PubMed: 11445622]
148.
Wagenknecht LE, Furberg CD, Hammon JW. et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ. 1995;310(6982):776–777. [PMC free article: PMC2549165] [PubMed: 7711582]
149.
Arnold M, Schroth G, Nedeltchev K. et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke. 2002;33(7):1828–1833. [PubMed: 12105361]
150.
Bourekas EC, Slivka AP, Shah R. et al. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. Neurosurgery. 2004;54(1):39–44. [PubMed: 14683539]
151.
Egan R, Clark W, Lutsep H. et al. Efficacy of intraarterial thrombolysis of basilar artery stroke. J Stroke Cardiovasc Dis. 1999;8(1):22–27. [PubMed: 17895133]
152.
IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.[see comment]. Stroke 2004; 35(4):904–911. [PubMed: 15017018]
153.
Qureshi AI, Ali Z, Suri MF. et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery. 2001;49(1):41–48. [PubMed: 11440458]
154.
Sylaja PN, Kuruttukulam G, Joseph S. et al. Selective intra arterial thrombolysis in acute carotid territory stroke. Neurol India. 2001;49(2):153–157. [PubMed: 11447435]
155.
Qureshi AI, Siddiqui AM, Suri MF. et al. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery. 2002;51(5):1319–1327. [PubMed: 12383381]
156.
Suwanwela NC, Phanthumchinda K, Suwanwela N. et al. Thrombolytic treatment for acute ischemic stroke: a 2 year-experience at King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2001;84(Suppl 1):S428–S436. [PubMed: 11529370]
157.
Hill MD, Barber PA, Demchuk AM. et al. Acute intravenous--intra-arterial revascularization therapy for severe ischemic stroke. Stroke. 2002;33(1):279–282. [PubMed: 11779923]
158.
Yoneda Y, Mori E, Uehara T. et al. Intracarotid regional infusion of recombinant tissue plasminogen activator for acute hemispheric stroke. Cerebrovasc Dis. 1998;8:357–359. [PubMed: 9845842]
159.
Barr JD, Mathis JM, Wildenhain SL. et al. Acute stroke intervention with intraarterial urokinase infusion. J Vasc Interv Radiol. 1994;5(5):705–713. [PubMed: 8000119]
160.
Ueda T, Hatakeyama T, Kumon Y. et al. Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT. Stroke. 1994;25(2):298–303. [PubMed: 8303735]
161.
Baltacioglu F, Afsar N, Ekinci G. et al. Intraarterial thrombolysis with r-tPA for treatment of anterior circulation acute ischemic stroke: Technical and clinical results. Intervent Neuroradiol. 2003;9(3):273–282. [PMC free article: PMC3548212] [PubMed: 20591253]
162.
Fitt GJ, Farrar J, Baird AE. et al. Intra-arterial streptokinase in acute ischaemic stroke. A pilot study. Med J Aust. 1993;159(5):331–334. [PubMed: 8361430]
163.
Gonner F, Remonda L, Mattle H. et al. Local intra-arterial thrombolysis in acute ischemic stroke. Stroke. 1998;29(9):1894–1900. [PubMed: 9731615]
164.
Kase CS, Furlan AJ, Wechsler LR et al. Symptomatic intracranial hemorrhage after intraarterial thrombolysis with recombinant prourokinase in acute ischemic stroke: the PROACT II Study. Neurology 2000; 54(Suppl 3).
165.
Kidwell CS, Saver JL, Carneado J. et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis.[see comment] Stroke. 2002;33(3):717–724. [PubMed: 11872894]
166.
Kidwell CS, Saver JL, Starkman S. et al. Late secondary ischemic injury in patients receiving intraarterial thrombolysis.[see comment] Ann Neurol. 2002;52(6):698–703. [PubMed: 12447922]
167.
Moazami N, Smedira NG, McCarthy PM. et al. Safety and efficacy of intraarterial thrombolysis for perioperative stroke after cardiac operation.[see comment] Ann Thorac Surg. 2001;72(6):1933–1937. [PubMed: 11789774]
168.
Qureshi AI, Suri MF, Shatla AA. et al. Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.[see comment] Neurosurgery. 2000;47(2):473–476. [PubMed: 10942026]
169.
Tong DD. Intra-arterial thrombolytic therapy for acute stroke: the debate continues.[comment] Stroke. 2002;33(7):1827. [PubMed: 12109492]
170.
Zaidat OO, Suarez JI, Santillan C. et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion.[see comment] Stroke. 2002;33(7):1821–1826. [PubMed: 12105360]
171.
Hahnel S, Schellinger PD, Gutschalk A. et al. Local intra-arterial fibrinolysis of thromboemboli occurring during neuroendovascular procedures with recombinant tissue plasminogen activator. Stroke. 2003;34(7):1723–1728. [PubMed: 12805492]
172.
Comerota AJ, Eze AR. Intraoperative high-dose regional urokinase infusion for cerebrovascular occlusion after carotid endarterectomy. J Vasc Surg. 1996;24(6):1008–1016. [PubMed: 8976354]
173.
Restrepo L, Pradilla G, Llinas R. et al. Perfusion- and diffusion-weighted MR imaging-guided therapy of vertebral artery dissection: intraarterial thrombolysis through an occipital vertebral anastomosis. AJNR Am J Neuroradiol. 2003;24(9):1823–1826. [PMC free article: PMC7976291] [PubMed: 14561610]
174.
Wardlaw JM, Lindley RI, Warlow CP. et al. A pilot study of intra-arterial thrombolysis for acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 1994;57:251.
175.
Ducrocq X, Anxionnat R, Taillandier L et al. Intravenous versus intra-arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients. Cerebrovasc Dis 2000; 10(Suppl 2).
176.
The E.M.S.Bridging Trial Investigators. Combined intravenous/intra-arterial thrombolytic therapy: safety, time to treatment, and frequency of clot. Stroke 1996 27 (1):165.
177.
Emergency Management of Stroke (EMS) Investigators. Combined intra-arterial and intravenous tPA for stroke. Stroke 1997; 28(1):273.
178.
Lee DH, Jo KD, Kim HG. et al. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol. 2002;13(8):769–774. [PubMed: 12171979]
179.
Zeumer H, Freitag HJ, Zanella F. et al. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology. 1993;35(2):159–162. [PubMed: 8433796]
180.
Wechsler LR, Roberts R, Furlan AJ. et al. Factors influencing outcome and treatment effect in PROACT II. Stroke. 2003;34(5):1224–1229. [PubMed: 12677011]
181.
Ueda T, Sakaki S, Nochide I. et al. Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries. Stroke. 1998;29(12):2568–2574. [PubMed: 9836769]
182.
Alexandrov AV, Demchuk AM, Burgin WS. et al. Ultrasound-enhanced thrombolysis for acute ischemic stroke: Phase I. findings of the CLOTBUST trial. J Neuroimaging. 2004;14(2):113–117. [PubMed: 15095555]
183.
Kerber CW, Barr JD, Berger RM. et al. Snare retrieval of intracranial thrombus in patients with acute stroke. J Vasc Interv Radiol. 2002;13(12):1269–1274. [PubMed: 12471193]
184.
Yoneyama T, Nakano S, Kawano H. et al. Combined direct percutaneous transluminal angioplasty and low-dose native tissue plasminogen activator therapy for acute embolic middle cerebral artery trunk occlusion. AJNR Am J Neuroradiol. 2002;23(2):277–281. [PMC free article: PMC7975249] [PubMed: 11847054]
185.
Mayer TE, Hamann GF, Brueckmann HJ. Treatment of basilar artery embolism with a mechanical extraction device: necessity of flow reversal.[see comment] Stroke. 2002;33(9):2232–2235. [PubMed: 12215592]
186.
Lin DDM, Gailloud P, Beauchamp NJ. et al. Combined stent placement and thrombolysis in acute vertebrobasilar ischemic stroke. AJNR Am J Neuroradiol. 2003;24(9):1827–1833. [PMC free article: PMC7976283] [PubMed: 14561611]
187.
Nakano S, Iseda T, Yoneyama T. et al. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis.[see comment] Stroke. 2002;33(12):2872–2876. [PubMed: 12468784]
188.
Alexandrov AV. Ultrasound-enhanced thrombolysis for stroke: clinical significance. Eur J Ultrasound. 2002;16(12):131–140. [PubMed: 12470858]
189.
Alexandrov AV, Wojner AW, Grotta JC. et al. CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. J Neuroimaging. 2004;14(2):108–112. [PubMed: 15095554]
190.
Marler J, Tilley BC, Lu M. et al. Earlier treatment associated with better outcomes in the NINDS tPA stroke study [Abstract] Stroke. 1999;30(1):244.
191.
Albers GW, Clark WM, for the ATLANTIS Study Investigators. The ATLANTIS rt-PA (Alteplase) acute stroke trial: final results. Cerebrovasc Dis 1999; 9(Suppl 1).
192.
Steiner T, Bluhmki E, Kaste M. et al. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. Cerebrovasc Dis. 1998;8(4):198–203. [PubMed: 9684058]
193.
Brott TG, Haley EJ, Levy DE. et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23(5):632–640. [PubMed: 1579958]
194.
Collins DR, O'Neill D, McCormack PM. Potential for treatment with thrombolysis in an Irish stroke unit. Ir Med J. 1999;92(1):236–238. [PubMed: 10360096]
195.
Hacke W, Donnan G, Fieschi C. et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–774. [PubMed: 15016487]
196.
Haring HP, Dilitz E, Pallua A. et al. Attenuated corticomedullary contrast: An early cerebral computed tomography sign indicating malignant middle cerebral artery infarction. A case-control study.[see comment] Stroke. 1999;30(5):1076–1082. [PubMed: 10229747]
197.
Silver B, Demaerschalk B, Merino JG. et al. Improved outcomes in stroke thrombolysis with pre-specified imaging criteria.[see comment] Can J Neurol Sci. 2001;28(2):113–119. [PubMed: 11383934]
198.
Lev MH, Segal AZ, Farkas J. et al. Utility of perfusion-weighted CT imaging in acute middle cerebral artery stroke treated with intra-arterial thrombolysis: prediction of final infarct volume and clinical outcome. Stroke. 2001;32(9):2021–2028. [PubMed: 11546891]
199.
von Kummer R, Allen KL, Holle R. et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy.[see comment] Radiology. 1997;205(2):327–333. [PubMed: 9356611]
200.
Barber PA, Demchuk AM, Hudon ME. et al. Hyperdense sylvian fissure MCA “dot” sign: A CT marker of acute ischemia. Stroke. 2001;32(1):84–88. [PubMed: 11136919]
201.
Larrue V, von K, RR MA. et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438–441. [PubMed: 11157179]
202.
von Kummer R. , Bourquain H, Bastianello S et al. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology. 2001;219(1):95–100. [PubMed: 11274542]
203.
Pexman JH, Barber PA, Hill MD. et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol. 2001;22(8):1534–1542. [PMC free article: PMC7974585] [PubMed: 11559501]
204.
Hill MD, Rowley HA, Adler F. et al. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS.[see comment] Stroke. 2003;34(8):1925–1931. [PubMed: 12843342]
205.
Wardlaw JM, Lindley RI, Lewis S. Thrombolysis for acute ischemic stroke: still a treatment for the few by the few. Western Journal of Medicine. 2002;176(3):198–199. [PMC free article: PMC1071716] [PubMed: 12016247]
206.
Chalela JA, Kang DW, Luby M. et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol. 2004;55(1):105–112. [PubMed: 14705118]
207.
Neumann-Haefelin T, Du Mesnil, Fiebach DR. et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke. 2004;35(1):109–114. [PubMed: 14671246]
208.
Tong DC, Adami A, Moseley ME. et al. Prediction of hemorrhagic transformation following acute stroke: role of diffusion- and perfusion-weighted magnetic resonance imaging.[see comment] Arch Neurol. 2001;58(4):587–593. [PubMed: 11295989]
209.
O'Rourke F, Akhtar N, Emery D. et al. Use of MRI in the identification and treatment of early ischemic stroke lesions. CMAJ. 2004;170(3):335–336. [PMC free article: PMC331381] [PubMed: 14757667]
210.
Kim Y-B, Lee K-H, Lee SJ. et al. Safety and efficacy of intravenous thrombolysis with tissue plasminogen activator using triphasic perfusion CT in acute ischemic stroke. Cerebrovasc Dis. 2000;10(Suppl 2):78.
211.
Lee K, Lee S, Kim Y. et al. Usefulness of triphasic perfusion CT for intravenous thrombolysis with tissue plasminogen activator in acute ischemic stroke. Stroke. 2000;31(11):2889. [PubMed: 10891982]
212.
Koenig M, Kraus M, Theek C. et al. Quantitative assessment of the ischemic brain by means of perfusion-related parameters derived from perfusion CT. Stroke. 2001;32(2):431–437. [PubMed: 11157178]
213.
Lee KH, Lee SJ, Cho SJ. et al. Usefulness of triphasic perfusion computed tomography for intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke. Arch Neurol. 2000;57(7):1000–1008. [PubMed: 10891982]
214.
Barsan WG, Brott TG, Broderick JP. et al. Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients. Stroke. 1994;25(11):2132–2137. [PubMed: 7974533]
215.
Smith WS, Corry MD, Fazackerley J. et al. Improved paramedic sensitivity in identifying stroke victims in the prehospital setting. Prehosp Emerg Care. 1999;3(3):207–210. [PubMed: 10424857]
216.
Becker K, Fruin M, Gooding T. et al. Community-based education improves stroke knowledge. Cerebrovasc Dis. 2001;11(1):34–43. [PubMed: 11173792]
217.
Morgenstern LB, King M, Staub L. et al. Community and professional intervention to increase FDA-approved acute stroke therapy: final main results of the TLL Temple Foundation stroke project. Neurology. 2001;56(Suppl 3):A77.
218.
Weinhardt J, Parker C. Developing a patient education video as a tool to case manage patients who have had strokes. Nurs Case Manag. 1999;4(4):198–200. [PubMed: 10690108]
219.
Alberts MJ, Perry A, Dawson DV. et al. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke. 1992;23(3):352–356. [PubMed: 1542895]
220.
Williams JE, Rosamond WD, Morris DL. Stroke symptom attribution and time to emergency department arrival: the delay in accessing stroke healthcare study. Acad Emerg Med. 2000;7(1):93–96. [PubMed: 10894250]
221.
Morgenstern LB, Staub L, Chan W. et al. Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project. Stroke. 2002;33(1):160–166. [PubMed: 11779906]
222.
Tuomilehto J, Sarti C, Narva EV. et al. The FINMONICA Stroke Register. Community-based stroke registration and analysis of stroke incidence in Finland, 1983-1985. Am J Epidemiol. 1992;135(11):1259–1270. [PubMed: 1626542]
223.
Buchan AM, Barber PA, Newcommon N. et al. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology. 2000;54(3):679–684. [PubMed: 10680803]
224.
Rapp K, Bratina P, Barch C. et al. Code Stroke: rapid transport, triage and treatment using rt-PA therapy. The NINDS rt-PA Stroke Study Group. [Review] [10 refs] Journal of Neuroscience Nursing. 1997;29(6):361–366. [PubMed: 9479657]
225.
Albers GW, Bates VE, Clark WM. et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.[see comment] JAMA. 2000;283(9):1145–1150. [PubMed: 10703776]
226.
Figueira FF. Stroke study group. Preliminary results. Early intensive care improves functional outcome. Arq Neuropsiquiatr. 1994;52(3):330–338. [PubMed: 7893206]
227.
Wester P, Radberg J, Lundgren B. et al. Factors associated with delayed admission to hospital and in-hospital delays in acute stroke and TIA: a prospective, multicenter study. Seek-Medical-Attention-in-Time Study Group. Stroke. 1999;30(1):40–48. [PubMed: 9880386]
228.
Moulin T, Sablot D, Vidry E. et al. Impact of emergency room neurologists on patient management and outcome. Eur Neurol. 2003;50(4):207–214. [PubMed: 14634264]
229.
Pearson BJ, Bath PM, Spence JD. Hypertension in patients presenting with stroke. [Review] [66 refs] Current Hypertension Reports. 2000;2(6):551–557. [PubMed: 11062601]
230.
Tilley BC, Lyden PD, Brott TG. et al. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol. 1997;54(12):1466–1474. [PubMed: 9400355]
231.
Chiu D, Krieger D, Villar-Cordova C. et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice.[see comment] Stroke. 1998;29(1):18–22. [PubMed: 9445322]
232.
Oswald N, Bateman H. Applying research evidence to individuals in primary care: a study using non-rheumatic atrial fibrillation. Family Practice. 1999;16(4):414–419. [PubMed: 10493714]
233.
Fernandes HM, Gregson B, Siddique S. et al. Surgery in intracerebral hemorrhage. The uncertainty continues. Stroke. 2000;31(10):2511–2516. [PubMed: 11022087]
234.
Qureshi AI, Tuhrim S, Broderick JP. et al. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344(19):1450–1460. [PubMed: 11346811]
235.
Barnett HJ, Mohr JP, Stein BM et al. Stroke Pathophysiology, Diagnosis, and Management. 3rd Edition. 1989. New York, Churchill Livingstone.
236.
Stroke pathophysiology, diagnosis, and management. 3.1998. New York, Chruchill Livingstone. 1998.
237.
Safar P. Amelioration of post-ischemic brain damage with barbiturates. Stroke. 1980;11(5):565–568. [PubMed: 6775398]
238.
Thomas DJ. Treatment of acute stroke. Br Med J (Clin Res Ed). 1984;288(6410):2–3. [PMC free article: PMC1444174] [PubMed: 6418298]
239.
Haley EC Jr. High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators. Stroke. 1998;29(6):1256–1257. [PubMed: 9626304]
240.
McDonald ES, Windebank AJ. Mechanisms of neurotoxic injury and cell death. Neurol Clin. 2000;18(3):525–540. [PubMed: 10873229]
241.
Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33(8):2123–2136. [PubMed: 12154275]
242.
Hoyte L, Kaur J, Buchan AM. Lost in translation: taking neuroprotection from animal models to clinical trials. Exp Neurol. 2004;188(2):200–204. [PubMed: 15246820]
243.
Weir CJ, Kaste M, Lees KR. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy. Stroke. 2004;35(9):2111–2116. [PubMed: 15243146]
244.
Recommendations for ensuring early thrombolytic therapy for acute myocardial infarction. The Heart and Stroke Foundation of Canada, the Canadian Cardiovascular Society and the Canadian Association of Emergency Physicians for the Emergency Cardiac Care Coalition.[see comment]. CMAJ 1996; 154(4):483–487. [PMC free article: PMC1487599] [PubMed: 8630837]
245.
Davis SM. Emergency management of stroke - Australasian Journal of Emergency Care. 1998;5(2):10–12.
246.
Norris JW, Buchan A, Cote R. et al. Canadian guidelines for intravenous thrombolytic treatment in acute stroke. A consensus statement of the Canadian Stroke Consortium. Can J Neurol Sci. 1998;25(3):257–259. [PubMed: 9706731]
247.
Hill MD, Buchan AM. Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators.[erratum appears in Can J Neurol Sci 2002 Feb;29(1):103] Can J Neurol Sci. 2001;28(3):232–238. [PubMed: 11513342]
248.
Dishaw A. Ontario Stroke Strategy Monitoring and Evaluation Committee Draft Report. 2003.
249.
Wardlaw JM, Zoppo G, Yamaguchi T et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003;(3):CD000213. [PubMed: 12917889]
250.
Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003;34(12):2847–2850. [PubMed: 14605319]
251.
Broderick JP, Adams HP Jr., Barsan W. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30(4):905–915. [PubMed: 10187901]
252.
Weir CJ, Murray GD, Dyker AG. et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study.[see comment] BMJ. 1997;314(7090):1303–1306. [PMC free article: PMC2126557] [PubMed: 9158464]
253.
Adams HP, Adams RJ, Brott T. et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34(4):1056–1083. [PubMed: 12677087]
254.
Gobin YP, Starkman S, Duckwiler GR. et al. MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia14564. Stroke. 2004;35(12):2848–2854. [PubMed: 15514171]
255.
CASES Investigators. The Canadian Alteplase for Stroke Effectiveness Study (CASES) 14563. CMAJ. In press.
256.
Barber PA, Demchuk AM, Zhang J. et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355(9216):1670–1674. [PubMed: 10905241]
257.
Ostergaard L, Weisskoff RM, Chesler DA. et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med. 1996;36(5):715–725. [PubMed: 8916022]
258.
Baird AE, Warach S. Magnetic resonance imaging of acute stroke. J Cereb Blood Flow Metab. 1998;18(6):583–609. [PubMed: 9626183]
259.
Butcher K, Parsons M, Baird T. et al. Perfusion thresholds in acute stroke thrombolysis. Stroke. 2003;34(9):2159–2164. [PubMed: 12893953]
260.
Statistics Canada. Age Standardized Mortality Rates. Available at: Internet 2004.
261.
Newby LK, Rutsch WR, Califf RM. et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol. 1996;27(7):1646–1655. [PubMed: 8636549]
262.
White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation. 1998;97(16):1632–1646. [PubMed: 9593569]
263.
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343(8893):311–322. [PubMed: 7905143]
264.
Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1(8478):397–402. [PubMed: 2868337]
265.
Raczynski JM, Finnegan JR Jr., Zapka JG. et al. REACT theory-based intervention to reduce treatment-seeking delay for acute myocardial infarction. Rapid Early Action for Coronary Treatment. Am J Prev Med. 1999;16(4):325–334. [PubMed: 10493291]
266.
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–1892. [PMC free article: PMC1557642] [PubMed: 10861325]
267.
Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886. [PubMed: 10861324]
268.
Deeks JJ, Dinnes J, D'Amico R et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7(27):iii-173. [PubMed: 14499048]
269.
Evaluating non-randomized intervention studies. European Carotid Surgery Trial Collaborative Group. Health Technol Assess 7(27), 1–173. 2003. [PubMed: 14499048]
270.
Marshall M, Lockwood A, Bradley C. et al. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry. 2000;176:249–252. [PubMed: 10755072]
271.
Engels EA, Schmid CH, Terrin N. et al. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med. 2000;19(13):1707–1728. [PubMed: 10861773]
272.
Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med. 1998;17(8):841–856. [PubMed: 9595615]

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...